Episode 28 - NF1-PN Podcast: Key Advances from AAN 2026

Episode 33 - Advanced Therapies and the Future of Uncontrolled Gout

Managing uncontrolled gout isn’t always straightforward—especially when flares persist, comorbidities complicate care, or standard therapies fall short. As our understanding of gout expands beyond just elevated uric acid, clinicians are being asked to think differently, integrating immune pathways, real-world evidence, and emerging treatments into everyday practice. From Refractory to Resolved: Rethinking Uncontrolled Gout in 2026, this CME-accredited podcast explores how to approach these complex cases with greater clarity and confidence. Featuring expert insights and the latest clinical evidence, each episode dives into practical strategies across the continuum of gout care. Listeners will hear discussions on advances in uricase-based therapies, selective URAT1 inhibitors, and inflammation-targeted treatments, along with key considerations around safety, sequencing, and collaborative care. Through real-world examples and focused conversations, this series equips clinicians with actionable tools to personalize treatment, address therapeutic challenges, and improve long-term outcomes for patients living with uncontrolled gout. Launch Date/Release: June 12, 2026 Expiration Date: May 31, 2027 FACULTY Robert Terkeltaub, MD Professor Emeritus of Medicine, University of California, San Diego This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link [https://www.practicepointcme.com/CMEHome/uncontrolled-gout-podcasts-rethinking-ug-in-2026] prior to listening to this podcast.

Episode 32 - Optimizing Gout Care Across the Disease Continuum

Managing uncontrolled gout isn’t always straightforward—especially when flares persist, comorbidities complicate care, or standard therapies fall short. As our understanding of gout expands beyond just elevated uric acid, clinicians are being asked to think differently, integrating immune pathways, real-world evidence, and emerging treatments into everyday practice. From Refractory to Resolved: Rethinking Uncontrolled Gout in 2026, this CME-accredited podcast explores how to approach these complex cases with greater clarity and confidence. Featuring expert insights and the latest clinical evidence, each episode dives into practical strategies across the continuum of gout care. Listeners will hear discussions on advances in uricase-based therapies, selective URAT1 inhibitors, and inflammation-targeted treatments, along with key considerations around safety, sequencing, and collaborative care. Through real-world examples and focused conversations, this series equips clinicians with actionable tools to personalize treatment, address therapeutic challenges, and improve long-term outcomes for patients living with uncontrolled gout. Launch Date/Release: June 12, 2026 Expiration Date: May 31, 2027 FACULTY Robert Terkeltaub, MD Professor Emeritus of Medicine, University of California, San Diego This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link [https://www.practicepointcme.com/CMEHome/uncontrolled-gout-podcasts-rethinking-ug-in-2026] prior to listening to this podcast.

Episode 31 - Beyond the Joint: The Burden and Biology of Uncontrolled Gout

Managing uncontrolled gout isn’t always straightforward—especially when flares persist, comorbidities complicate care, or standard therapies fall short. As our understanding of gout expands beyond just elevated uric acid, clinicians are being asked to think differently, integrating immune pathways, real-world evidence, and emerging treatments into everyday practice. From Refractory to Resolved: Rethinking Uncontrolled Gout in 2026, this CME-accredited podcast explores how to approach these complex cases with greater clarity and confidence. Featuring expert insights and the latest clinical evidence, each episode dives into practical strategies across the continuum of gout care. Listeners will hear discussions on advances in uricase-based therapies, selective URAT1 inhibitors, and inflammation-targeted treatments, along with key considerations around safety, sequencing, and collaborative care. Through real-world examples and focused conversations, this series equips clinicians with actionable tools to personalize treatment, address therapeutic challenges, and improve long-term outcomes for patients living with uncontrolled gout. Launch Date/Release: June 12, 2026 Expiration Date: May 31, 2027 FACULTY Robert Terkeltaub, MD Professor Emeritus of Medicine, University of California, San Diego This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link [https://www.practicepointcme.com/CMEHome/uncontrolled-gout-podcasts-rethinking-ug-in-2026] prior to listening to this podcast.

Episode 30 - Days 3 and 4: Key Breakthroughs from EASL 2026

These podcast episodes explore the rapidly evolving treatment landscape of Primary Biliary Cholangitis, highlighting recent therapeutic advances and reviews emerging clinical evidence on promising investigational therapies. Designed for healthcare professionals, these episodes provides expert commentary on the latest cutting-edge data presented at EASL Congress 2026. Through an engaging podcast format, listeners will gain practical insights into how new evidence can inform personalized treatment strategies, support improved patient outcomes, and enhance the overall quality of care for people living with PBC. Launch Date/Release: June 3, 2026 Expiration Date: May 31, 2027 FACULTY Kris V. Kowdley, MD, AGAF, FAASLD, FACG, FACP Liver Institute Northwest Director, Velocity Clinical Research Medical Director and Senior Scientific Advisor Washington State University Elson S. Floyd College of Medicine – Professor This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link [https://www.practicepointcme.com/CMEHome/pbc-podcast-key-breakthroughs-from-easl-2026] prior to listening to this podcast.

Episode 29 - Days 1 and 2: Key Breakthroughs from EASL 2026

These podcast episodes explore the rapidly evolving treatment landscape of Primary Biliary Cholangitis, highlighting recent therapeutic advances and reviews emerging clinical evidence on promising investigational therapies. Designed for healthcare professionals, these episodes provides expert commentary on the latest cutting-edge data presented at EASL Congress 2026. Through an engaging podcast format, listeners will gain practical insights into how new evidence can inform personalized treatment strategies, support improved patient outcomes, and enhance the overall quality of care for people living with PBC. Launch Date/Release: June 3, 2026 Expiration Date: May 31, 2027 FACULTY Kris V. Kowdley, MD, AGAF, FAASLD, FACG, FACP Liver Institute Northwest Director, Velocity Clinical Research Medical Director and Senior Scientific Advisor Washington State University Elson S. Floyd College of Medicine – Professor This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link [https://www.practicepointcme.com/CMEHome/pbc-podcast-key-breakthroughs-from-easl-2026] prior to listening to this podcast.